NCT04121169View on ClinicalTrials.gov

Treatment of Mild-moderate Clostridium Difficile Infection (CDI)

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

December 30, 2023

Study Completion Date

March 30, 2024

Conditions
Clostridium Difficile Infection (CDI)
Interventions
DRUG

IM-01

Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile

Trial Locations (1)

T2N 2T9

RECRUITING

Foothills Medical Center, Calgary

Sponsors

Lead Sponsor

ImmuniMed Inc.
All Listed Sponsors
collaborator

University of Calgary

OTHER

collaborator

University of Manitoba

OTHER

lead

ImmuniMed Inc.

INDUSTRY

NCT04121169 - Treatment of Mild-moderate Clostridium Difficile Infection (CDI) | Biotech Hunter | Biotech Hunter